Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Rudick

Showing results (21-30 of 188) with videos related to

Pageof 19
Sort By:
Annals of Neurology|September 1, 1983
Neuropathological features of a lupus-like disorder in autoimmune miceR A Rudick, T A Eskin
Nature Clinical Practice. Neurology|August 26, 2006
Drug Insight: interferon treatment in multiple sclerosisRuth Ann Marrie, Richard A Rudick
Dermatology Online Journal|March 1, 1997
Painful leg lesions: a case reportE Zabawski, L Dollison, A Rudick
Science Translational Medicine|December 1, 2012
Time to integrate clinical and research informaticsIrene L Katzan, Richard A Rudick
Science Translational Medicine|April 5, 2013
Author response to comment on "time to integrate clinical and research informatics"Irene L Katzan, Richard A Rudick
Biologics : Targets & Therapy|August 27, 2009
Natalizumab for the treatment of relapsing multiple sclerosisRichard A Rudick, Michael A Panzara
Neurology|April 28, 2010
Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of lifeDeborah Miller, Richard A Rudick, Michael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 3, 2002
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trialsR A Rudick, G Cutter, S Reingold
Archives of Neurology|October 1, 1987
The GABA-agonist progabide for spasticity in multiple sclerosisR A Rudick, D Breton, R L Krall
Archives of Neurology|October 1, 1989
Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trialsD E Goodkin, D Hertsgaard, R A Rudick
Pageof 19

Showing results (21-30 of 188) with videos related to

Sort By:
Pageof 19
Annals of Neurology|September 1, 1983
Neuropathological features of a lupus-like disorder in autoimmune miceR A Rudick, T A Eskin
Nature Clinical Practice. Neurology|August 26, 2006
Drug Insight: interferon treatment in multiple sclerosisRuth Ann Marrie, Richard A Rudick
Dermatology Online Journal|March 1, 1997
Painful leg lesions: a case reportE Zabawski, L Dollison, A Rudick
Science Translational Medicine|December 1, 2012
Time to integrate clinical and research informaticsIrene L Katzan, Richard A Rudick
Science Translational Medicine|April 5, 2013
Author response to comment on "time to integrate clinical and research informatics"Irene L Katzan, Richard A Rudick
Biologics : Targets & Therapy|August 27, 2009
Natalizumab for the treatment of relapsing multiple sclerosisRichard A Rudick, Michael A Panzara
Neurology|April 28, 2010
Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of lifeDeborah Miller, Richard A Rudick, Michael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 3, 2002
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trialsR A Rudick, G Cutter, S Reingold
Archives of Neurology|October 1, 1987
The GABA-agonist progabide for spasticity in multiple sclerosisR A Rudick, D Breton, R L Krall
Archives of Neurology|October 1, 1989
Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trialsD E Goodkin, D Hertsgaard, R A Rudick
Pageof 19